Spero Therapeutics is trading 5.83% up at $1.27 in pre-market, with no clear catalyst identified for the October 12 move. - Its latest listed release was an October 2 inducement-grant announcement; it does not establish a direct catalyst. - The broader market backdrop was mildly positive, but biotech was not clearly participating: XBI was reported down 0.4% on October 12. - Available evidence does not establish a clear company-, sector-, or market-wide reason for the move.